Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Article Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
November 15, 2023
One of the most salient lessons from the pandemic is the need to diversify manufacturing capabilities and bolster supply resilience to avoid a repeat of the slow and inequitable vaccine roll out in African countries. To turn this lesson into action, the Gavi Secretariat is rapidly advancing plans fo...
Blog Post
August 16, 2023
Despite verbal nods to global cooperation, equity, and solidarity, the COVID-19 pandemic laid bare a brutal realpolitik: all countries will put their citizens first and vaccinate their own populations, before offering charitable leftovers beyond their own borders. Sub-Saharan Africa, more than any o...
Blog Post
August 07, 2023
While donors are increasingly interested in both promoting evidence-based policymaking and advancing locally led development, the two agendas have often remained separate. This is a missed opportunity. A recent CGD working group underscored the value of locally immersed researchers and organizations...
POLICY PAPERS
August 07, 2023
CGD conducted a landscaping exercise to better understand the current landscape of organizations headquartered in sub-Saharan Africa that boast impact evaluation capacity. The resulting database is intended as a resource for funders looking to advance locally led development; to help facilitate coor...
Jul
20
2023
VIRTUAL
10:00—11:00 AM ET / 3:00-4:00 PM BST
June 14, 2023
Join the Center for Global Development for a virtual panel discussion reflecting on lessons learned from COVAX for future global and regional response efforts to ensure rapid and equitable access to vaccines and other medical countermeasures.
Blog Post
March 07, 2023
The EU and its member states are collectively the world’s largest aid donor, with an annual budget of over $70 billion in 2021. When it comes to global health, however, it has historically punched below its weight. In part, this is due to an internal coordination problem; health is a shared competen...
Mar
7
2023
VIRTUAL
9:30—10:45 AM Eastern Time (US and Canada)
February 27, 2023
Following promising clinical trial results, the first oral antiviral treatments for COVID-19 received emergency use authorization in late 2021. Since then, manufacturers, global health funders, and other partners have focused on ramping up global supply, including via test-and-treat pilot programs. ...
CGD NOTES
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...
Blog Post
December 14, 2022
Four new CGD pieces, released today, examine the current state of play on COVID-19 oral antivirals. Our analyses provide a deep-dive in key cross-cutting areas—demand, voluntary licensing deals for generic supply, and deployment—and offer policy actions for 2023 and beyond.
Blog Post
August 10, 2022
PEPFAR’s new strategy—to be released in final form later this year—focuses on how to accelerate progress toward epidemic control amidst continued impacts from COVID-19, while also strengthening core health system functions as well as partnership and coordination efforts; this is precisely what the c...